Cover Image
市場調查報告書

心肌梗塞:開發平台分析

Myocardial Infarction - Pipeline Review, H1 2017

出版商 Global Markets Direct 商品編碼 229746
出版日期 內容資訊 英文 307 Pages
訂單完成後即時交付
價格
Back to Top
心肌梗塞:開發平台分析 Myocardial Infarction - Pipeline Review, H1 2017
出版日期: 2017年03月31日 內容資訊: 英文 307 Pages
簡介

所謂心肌梗塞(或心臟缺血)是心肌供血、供氧不足造成的。 主要的症狀以胸痛(尤其是人體左側(心絞痛))為首,頸部、下巴疼痛、肩膀·手臂疼痛、冷汗、呼吸急促、噁心·嘔吐等。此外,也可因冠狀動脈疾病(動脈粥樣硬化)和血栓、冠狀血管痙攣、或其他重病造成發病。一般認為會增加罹患的危險因子有抽煙和糖尿病、高血壓、高膽固醇症(高甘油三酯血症)、運動不足、肥胖、家族病史等。

本報告提供全球各國治療心肌梗塞所用的開發中產品之開發情形相關分析,提供您產品開發·上市的最新趨勢,及臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。

目錄

簡介

  • 分析範圍

心肌梗塞概要

治療藥的開發

  • 心肌梗塞開發中產品:概要
  • 心肌梗塞開發中產品:比較分析

各企業開發中的心肌梗塞治療藥

大學/研究機關研究中的心肌梗塞治療藥

開發中產品的概要

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品
  • 不明確的階段有的產品

心肌梗塞治療藥:開發中的產品的一覽(各企業)

心肌梗塞治療藥:研究中的產品的一覽(大學/研究機關別)

心肌梗塞開發治療藥的企業

  • Amarantus Bioscience Holdings, Inc.
  • Angion Biomedica Corp.
  • Asterias Biotherapeutics, Inc.
  • AstraZeneca Plc
  • Athersys, Inc.
  • Bayer AG
  • Bharat Biotech International Limited
  • BioCardia, Inc.
  • Biscayne Pharmaceuticals, Inc.
  • Capricor Therapeutics, Inc.
  • CellProthera
  • Celyad SA
  • Compugen Ltd.
  • CSL Limited
  • Cynata Therapeutics Limited
  • FibroGen, Inc.
  • Hemostemix Ltd
  • Human Stem Cells Institute
  • HUYA Bioscience International, LLC
  • Immune Pharmaceuticals Inc.
  • Juventas Therapeutics, Inc.
  • Laboratoires Pierre Fabre SA
  • Lee's Pharmaceutical Holdings Limited
  • LegoChem Biosciences, Inc
  • LG Life Science LTD.
  • Medestea Research & Production S.p.A.
  • Mesoblast Limited
  • miRagen Therapeutics, Inc.
  • Moderna Therapeutics, Inc.
  • MorphoSys AG
  • NeuroVive Pharmaceutical AB
  • New World Laboratories, Inc.
  • Novartis AG
  • Omeros Corporation
  • 大塚集團
  • Pfizer Inc.
  • Polyphor Ltd.
  • Primary Peptides, Inc.
  • Quantum Genomics SA
  • Quark Pharmaceuticals, Inc.
  • Recardio GmbH
  • Serodus ASA
  • Silver Creek Pharmaceuticals, Inc.
  • Stealth BioTherapeutics Inc.
  • Stemedica Cell Technologies, Inc.
  • Stempeutics Research Private Limited
  • TaiGen Biotechnology Co., Ltd.
  • Targazyme, Inc.
  • The International Biotechnology Center (IBC) Generium
  • TiGenix NV
  • Vicore Pharma AB
  • XBiotech USA, Inc.
  • Yuyu Pharma, Inc.
  • Zydus Cadila Healthcare Limited

心肌梗塞:治療藥的評估

  • 單劑治療藥的情況
  • 並用治療藥的情況
  • 標的別
  • 各作用機制
  • 各投藥法
  • 各分子類型

藥物簡介

  • (sacubitril + valsartan)
  • AB-002
  • ACP-01
  • Alda-1
  • alteplase biosimilar
  • AMRS-001
  • ANG-4011
  • Antisense RNAi Oligonucleotide to Inhibit miR-92 for Myocardial Infarction
  • AP-102
  • APO-1
  • balixafortide
  • Biosimilar 3 for Rheumatoid Arthritis, Acute Myocardial Infarction and Inflammation
  • BIS-5409
  • bococizumab
  • burixafor
  • C-21
  • C3BSGQR-3
  • C3BSGQR-4
  • CAP-1001
  • CAP-1002
  • cenderitide
  • CGEN-856S
  • CIGB-500
  • CM-1
  • Cryocell
  • CSL-112
  • CTX-101
  • cyclosporine
  • Drugs to Inhibit Alpha Myosin for Cardiovascular Disorders
  • Drugs to Inhibit SIRT2 for Ischemic Stroke and Myocardial Infarction
  • dutogliptin tartrate
  • elamipretide
  • Ephrin A-1 for Myocardial Infarction
  • F-573
  • FG-6874
  • Gemacell
  • Gene Therapy for Acute Myocardial Infarction
  • HBI-3802
  • HYPER-IL-6
  • ICG-001
  • IS-20
  • JI-38
  • JVS-100
  • JVS-200
  • KR-33028
  • LC-280126
  • LWnt-3a
  • Lysimab
  • MGN-1374
  • MGN-6114
  • MIF-2
  • MIF-20
  • Monoclonal Antibodies to Inhibit IL-1a for Myocardial Infarction and Atherosclerosis
  • Monoclonal Antibody Conjugates to Target Mannose Receptor for Myocardial Infarction
  • MPC-150IM
  • MPC-25IC
  • Neu-2000
  • NP-202
  • NVP-019
  • NVX-308
  • NWL-53
  • Oligonucleotide for Oncology and Cardiovascular
  • Oligonucleotides for Cardiometabolic Diseases and Renal diseases
  • OMS-721
  • OPC-28326
  • Peptide to Activate G Protein-Coupled Receptor Mas for Cardiovascular, Metabolic Disorders and Erectile Dysfunction
  • Peptide to Agonize Apelin Receptor for Diabetes and Heart Failure
  • PF-05285401
  • Polyglactin 370 for Acute Myocardial Infarction
  • PP-001
  • Protein to Agonize LRP5 and LRP6 for Myocardial Infarction and Critical Limb Ischemia
  • ProtheraCytes
  • QGC-101
  • QPCP-1
  • RBB-001
  • Recombinant Protein for Cardiovascular Diseases
  • Recombinant Protein for Myocardial Infarction
  • Recombinant Proteins to Agonize IGF-1R for Myocardial Infarction
  • Recombinant Prourokinase
  • remestemcel-L
  • rivaroxaban
  • RNAi Oligonucleotide for Myocardial Infarction
  • salicylamine
  • SER-130
  • Small Molecule for Myocardial Infarction
  • Small Molecule for Reperfusion Injury and Heart Attack
  • Small Molecule to Inhibit Blood Factor XIa for CAHD and Stroke
  • Small Molecules for Myocardial Infarction and Inflammation
  • Small Molecules to Antagonize Adenosine A2B Receptor for Asthma and Myocardial Infarction
  • Small Molecules to Inhibit BAX for Myocardial Infarction
  • Small Molecules to Inhibit MMP for Myocardial Infarction
  • Small Molecules to Inhibit PARP for Immunology, Oncology, Cardiovascular and Metabolic Disorders
  • Small Molecules to Inhibit PDE5 for Cardiovascular Disease
  • Small Molecules to Scavenge Free Radicals for Oxidative Stress Related Disorders
  • Stem Cell Therapy for Acute Myocardial Infarction
  • Stem Cell Therapy for Cardiovacular Diseases
  • Stem Cell Therapy for Cardiovascular Disease, CNS Disorders, Metabolic Disorders, Respiratory Disease, Infectious Disease and Toxicology
  • Stem Cell Therapy for Cardiovascular Diseases
  • Stem Cell Therapy for Myocardial Infarction and Heart Failure
  • Stempeucel
  • Synthetic Peptide to Activate Erythropoietin Receptor for Cardiovascular Diseases
  • TF-0023
  • THR-100
  • ticagrelor
  • TZ-101
  • VN-100
  • ZK-001

心肌梗塞治療藥:開發中產品的最新趨勢

心肌梗塞治療藥:開發暫停的產品

心肌梗塞治療藥:開發中止的產品

心肌梗塞相關產品的開發的里程碑

  • 值得注意的最新趨勢·新聞稿

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9116IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Myocardial Infarction - Pipeline Review, H1 2017, provides an overview of the Myocardial Infarction (Cardiovascular) pipeline landscape.

Myocardial infarction is the irreversible necrosis of heart muscle secondary to prolonged ischemia. Symptoms include pain, fullness, and/or squeezing sensation of the chest, jaw pain, toothache, headache, shortness of breath, nausea, vomiting, and/or general epigastric discomfort, sweating, heartburn and/or indigestion, arm pain, upper back pain and general malaise (vague feeling of illness).

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Myocardial Infarction - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Myocardial Infarction (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Myocardial Infarction (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Myocardial Infarction and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 7, 14, 9, 37, 6 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 2, 20 and 7 molecules, respectively.

Myocardial Infarction (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Myocardial Infarction (Cardiovascular).
  • The pipeline guide reviews pipeline therapeutics for Myocardial Infarction (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Myocardial Infarction (Cardiovascular) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Myocardial Infarction (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Myocardial Infarction (Cardiovascular)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Myocardial Infarction (Cardiovascular).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Myocardial Infarction (Cardiovascular) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
  • Introduction
  • Myocardial Infarction - Overview
  • Myocardial Infarction - Therapeutics Development
  • Myocardial Infarction - Therapeutics Assessment
  • Myocardial Infarction - Companies Involved in Therapeutics Development
  • Myocardial Infarction - Drug Profiles
  • Myocardial Infarction - Dormant Projects
  • Myocardial Infarction - Discontinued Products
  • Myocardial Infarction - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Myocardial Infarction, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..3), H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..2), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..3), H1 2017
  • Products under Development by Universities/Institutes, H1 2017
  • Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..2), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..2), H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Myocardial Infarction - Pipeline by Amarantus Bioscience Holdings Inc, H1 2017
  • Myocardial Infarction - Pipeline by AstraZeneca Plc, H1 2017
  • Myocardial Infarction - Pipeline by Athersys Inc, H1 2017
  • Myocardial Infarction - Pipeline by Bayer AG, H1 2017
  • Myocardial Infarction - Pipeline by Bharat Biotech International Ltd, H1 2017
  • Myocardial Infarction - Pipeline by BioCardia Inc, H1 2017
  • Myocardial Infarction - Pipeline by Biscayne Pharmaceuticals Inc, H1 2017
  • Myocardial Infarction - Pipeline by Capricor Therapeutics Inc, H1 2017
  • Myocardial Infarction - Pipeline by CellProthera, H1 2017
  • Myocardial Infarction - Pipeline by Chrysalis BioTherapeutics Inc, H1 2017
  • Myocardial Infarction - Pipeline by Compugen Ltd, H1 2017
  • Myocardial Infarction - Pipeline by Cynata Therapeutics Limited, H1 2017
  • Myocardial Infarction - Pipeline by Diffusion Pharmaceuticals Inc, H1 2017
  • Myocardial Infarction - Pipeline by FibroGen Inc, H1 2017
  • Myocardial Infarction - Pipeline by Hemostemix Ltd, H1 2017
  • Myocardial Infarction - Pipeline by Human Stem Cells Institute, H1 2017
  • Myocardial Infarction - Pipeline by HUYA Bioscience International LLC, H1 2017
  • Myocardial Infarction - Pipeline by InCarda Therapeutics Inc, H1 2017
  • Myocardial Infarction - Pipeline by Inotrem SA, H1 2017
  • Myocardial Infarction - Pipeline by Juventas Therapeutics Inc, H1 2017
  • Myocardial Infarction - Pipeline by Laboratoires Pierre Fabre SA, H1 2017
  • Myocardial Infarction - Pipeline by Lee's Pharmaceutical Holdings Ltd, H1 2017
  • Myocardial Infarction - Pipeline by LG Chem, Ltd., H1 2017
  • Myocardial Infarction - Pipeline by Medestea Research & Production SpA, H1 2017
  • Myocardial Infarction - Pipeline by Mesoblast Ltd, H1 2017
  • Myocardial Infarction - Pipeline by Moderna Therapeutics Inc, H1 2017
  • Myocardial Infarction - Pipeline by Navya Biologicals Pvt Ltd, H1 2017
  • Myocardial Infarction - Pipeline by New World Laboratories Inc, H1 2017
  • Myocardial Infarction - Pipeline by Novartis AG, H1 2017
  • Myocardial Infarction - Pipeline by NuvOx Pharma LLC, H1 2017
  • Myocardial Infarction - Pipeline by Omeros Corp, H1 2017
  • Myocardial Infarction - Pipeline by Opsona Therapeutics Ltd, H1 2017
  • Myocardial Infarction - Pipeline by Otsuka Holdings Co Ltd, H1 2017
  • Myocardial Infarction - Pipeline by Pharmahungary Group, H1 2017
  • Myocardial Infarction - Pipeline by Primary Peptides Inc, H1 2017
  • Myocardial Infarction - Pipeline by Quark Pharmaceuticals Inc, H1 2017
  • Myocardial Infarction - Pipeline by Recardio GmbH, H1 2017
  • Myocardial Infarction - Pipeline by RegeneRx Biopharmaceuticals Inc, H1 2017
  • Myocardial Infarction - Pipeline by Reliance Life Sciences Pvt Ltd, H1 2017
  • Myocardial Infarction - Pipeline by Rubicon Biotechnology Inc, H1 2017
  • Myocardial Infarction - Pipeline by Serodus ASA, H1 2017
  • Myocardial Infarction - Pipeline by Silver Creek Pharmaceuticals Inc, H1 2017
  • Myocardial Infarction - Pipeline by Stemedica Cell Technologies Inc, H1 2017
  • Myocardial Infarction - Pipeline by TaiGen Biotechnology Co Ltd, H1 2017
  • Myocardial Infarction - Pipeline by Targazyme Inc, H1 2017
  • Myocardial Infarction - Pipeline by Tasly Pharmaceutical Group Co Ltd, H1 2017
  • Myocardial Infarction - Pipeline by The International Biotechnology Center (IBC) Generium, H1 2017
  • Myocardial Infarction - Pipeline by TiGenix NV, H1 2017
  • Myocardial Infarction - Pipeline by Vicore Pharma AB, H1 2017
  • Myocardial Infarction - Pipeline by XBiotech Inc, H1 2017
  • Myocardial Infarction - Pipeline by Yuyu Pharma Inc, H1 2017
  • Myocardial Infarction - Pipeline by Zydus Cadila Healthcare Ltd, H1 2017
  • Myocardial Infarction - Dormant Projects, H1 2017
  • Myocardial Infarction - Dormant Projects, H1 2017 (Contd..1), H1 2017
  • Myocardial Infarction - Dormant Projects, H1 2017 (Contd..2), H1 2017
  • Myocardial Infarction - Dormant Projects, H1 2017 (Contd..3), H1 2017
  • Myocardial Infarction - Dormant Projects, H1 2017 (Contd..4), H1 2017
  • Myocardial Infarction - Dormant Projects, H1 2017 (Contd..5), H1 2017
  • Myocardial Infarction - Discontinued Products, H1 2017

List of Figures

  • Number of Products under Development for Myocardial Infarction, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Top 10 Targets, H1 2017
  • Number of Products by Stage and Top 10 Targets, H1 2017
  • Number of Products by Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Top 10 Routes of Administration, H1 2017
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2017
  • Number of Products by Top 10 Molecule Types, H1 2017
  • Number of Products by Stage and Top 10 Molecule Types, H1 2017
Back to Top